Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04701684

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

La Sagrada Familia Clinic, José Hernández, Argentina

Loading trial locations.

About this study

Outcomes for stroke patients are closely tied to how fast they receive treatment. Currently, when a possible stroke patient arrives at the emergency department, typically first a CT or MRI exam is acquired for stroke triage. In case of an ischemic stroke the patient is then treated in an interventional suite.

In the DTAS workflow stroke patients are diagnosed and treated in the interventional suite without interruption. The Cone-Beam CT (CBCT) capabilities of the interventional X-ray system are utilized to perform triage, directly followed by stroke treatment.

The primary objective of the WE-TRUST study is to demonstrate that the DTAS triage workflow involving CBCT results in superior patient outcome in ischemic stroke patients with confirmed Large Vessel Occlusion as compared to the conventional CT/MR triage workflow.

The WE-TRUST study will be running in 16+ sites to enroll 500+ patients globally.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is 18 years of age or older, or of legal age to give informed consent per state or national law.
  • Baseline NIHSS score obtained prior to randomization must be equal or higher than 10 points.
  • Subjects with no significant pre-stroke functional disability (modified Rankin scale 0 - 2).
  • Subjects suspected of acute ischemic stroke with an estimated arrival time at a stroke center (clinical investigational site participating in this study) < 6 hours from symptom onset OR wake-up stroke with time last known well of < 12 hours and symptoms discovered within 6 hours from arrival time at a stroke center. Symptom onset is defined as point in time the patient was last known well (at baseline).
  • Informed consent obtained from patient or his or her legally designated representative (if locally required).
  • Angiography suite immediately available.
  • Endovascular treatment team immediately available (Neurologist, Neurointerventionalist, Anesthesiologist, Nursing, Technicians as per local standard practice)

Exclusion criteria

Clinical exclusion criteria:

  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0
  • Known baseline platelet count < 30.000/μL
  • Baseline blood glucose of < 50mg/dL (< 2.78mmol/l)
  • For patients receiving thrombolysis: severe, sustained hypertension (SBP > 185 mm Hg or DBP > 110 mm Hg). Note: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA/ASA guidelines recommended medication (including IV antihypertensive drips), the patient can be enrolled.
  • Patients from a transfer center (Primary Stroke Center) with a CT/MR that is not required to be redone in the Comprehensive Stroke Center as per discretion of the physician or per local standards (e.g. CT/MR less than 90 minutes old).
  • Patients in coma (NIHSS item of consciousness >1) defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).
  • Patients with extreme vomiting
  • Patients that are extremely agitated
  • Seizures at stroke onset which would preclude obtaining a baseline NIHSS
  • Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
  • Patients acquired stroke while in-hospital
  • History of life-threatening allergy (more than rash) to contrast medium
  • Cerebral vasculitis
  • Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)
  • Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).
  • Patients with unstable clinical status who require emergent life support care
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
  • Subject participates in a potentially confounding drug or device trial during the course of the study.
  • Woman of childbearing potential who is known to be pregnant on admission.
  • Subject meets an exclusion criteria according to national law (e.g. age, pregnant woman, breast feeding woman)
  • Subject is Philips employee or their family members residing with this Philips employee.

Treatment and study plan

Direct to Angio Suite (DTAS) Philips' CBCT triage

Device

Stroke patients are diagnosed and treated (mechanical thrombectomy) in the same angio suite

Conventional CT/MR triage

Procedure

First a CT or MRI exam is acquired for triage. In case of an ischemic stroke the patient is then treated in an interventional suite.

Primary outcomes

  1. Distribution of ordinal modified Rankin Scale (mRS) scores at 90 ± 14 days follow-up

    Time frame: 90 ± 14 days follow-up

    The difference in the distribution of ordinal modified Rankin Scale (mRS) scores at 90 ± 14 days follow-up in the Target population to determine the performance of the DTAS triage imaging workflow involving Stroke CBCT reconstructions by the investigational device or SmartCT R3 in comparison to the conventional CT/MR triage imaging workflow. The 90 day mRS score will be evaluated by a blinded assessor of a pool of blinded assessors (i.e., a specialist with mRS certification) at the local hospital by performing a structured interview of the patient in person using the Rankin Focused Assessment (RFA) structured mRS questionnaire. If the subject is unable to return to the clinic for the day 90 ± 14 visit, a (video) call in which the mRS score is assessed by a blinded assessor is preferable to no assessment.

Secondary outcomes

  1. Median time measurements (door-to-arterial puncture time)

    Time frame: Peri-procedural time

    Door-to-arterial puncture time: Time patient arrives at the Comprehensive Stroke Center door to the time the skin of the patient is touched to perform first arterial puncture.

  2. Median time measurements (door-to-reperfusion time)

    Time frame: Peri-procedural time

    Door-to-reperfusion time: Time patient arrives at the Comprehensive Stroke Center door to the time of successful vessel recanalization (eTICI ≥ 2b)

  3. Distribution of ordinal modified Rankin Scale (mRS) scores

    Time frame: 90 ± 14 days follow-up

    The distribution of ordinal modified Rankin Scale (mRS) scores at 90 ± 14 days follow-up in both arms in the Randomized population.

Other outcomes

  1. Safety: Adverse events (mortality at 90 days)

    Time frame: At 90 days post-procedure

    Mortality and stroke-related mortality

  2. Safety: Adverse events (symptomatic ICH)

    Time frame: At 24 (-12/+24) hours

    All intracranial hemorrhages will be classified by the blinded Core Lab using the Heidelberg Bleeding Classification. Symptomatic ICH will be defined as per a modified SITS-MOST definition [31]: Symptomatic intracranial hemorrhage is defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage on the 24 (-12/+24) hours post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline, or from the lowest NIHSS value between baseline and 24 (-12/+24) hours after randomization, or leading to death.

  3. Safety: Adverse events (asymptomatic ICH)

    Time frame: At 24 (-12/+24) hours

    All intracranial hemorrhages will be classified (blinded) by using the Heidelberg Bleeding Classification. All the intracranial hemorrhages which are not symptomatic, are classified as asymptomatic.

  4. Safety: Adverse events (other)

    Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)

    including information of the seriousness, treatment needed, resolution and relevant judgment concerning the causal relationship with the investigational device, SmartCT R3, comparator (CT/MR), or procedure will be summarized for safety information.

  5. Safety: Adverse Device Effects

    Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)

    including information of the seriousness, treatment needed, resolution and relevant judgment concerning the causal relationship with the investigational devices, released SmartCT R3 product or procedure will be summarized for safety information.

  6. Safety: Number of participants with Device Deficiencies that could have led to Serious Adverse Event

    Time frame: From start of enrollment until hospital discharge (e.g. up to 5 days)

    including any corrective actions taken during the study, if any, will be summarized for safety information.

  7. Exploratory: Median time measurements (door-to-randomization time)

    Time frame: Peri-procedural time

    Door-to-randomization time: Time patient arrives at the Comprehensive Stroke Center door to the time of randomization

  8. Exploratory: Median time measurements (door-to-imaging time)

    Time frame: Peri-procedural time

    Door-to-imaging time: Time patient arrives at the Comprehensive Stroke Center door to the time of initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR)

  9. Exploratory: Median time measurements (randomization-to-imaging time)

    Time frame: Peri-procedural time

    Randomization-to-imaging time: Time of randomization to the time of initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR)

  10. Exploratory: Median time measurements (randomization-to-puncture time)

    Time frame: Peri-procedural time

    Randomization-to-puncture time: Time of randomization to the time the skin of the patient is touched to perform first arterial puncture

  11. Exploratory: Median time measurements (door-to-thrombolytics administration time)

    Time frame: Peri-procedural time

    Door-to-thrombolytics administration time: Time patient arrives at the CSC door to the time of start of thrombolytics administration.

  12. Exploratory: Median time measurements (onset-to-door time)

    Time frame: Peri-procedural time

    Onset-to-door time: Time patient last seen well to the time the patient arrives at the Comprehensive Stroke Center door

  13. Exploratory: Median time measurements (onset-to-arterial puncture time)

    Time frame: Peri-procedural time

    Onset-to-arterial puncture time: Time patient last seen well to the time the skin of the patient is touched to perform first arterial puncture

  14. Exploratory: Median time measurements (onset-to-successful reperfusion (eTICI ≥ 2b) time)

    Time frame: Peri-procedural time

    Onset-to-successful reperfusion (eTICI ≥ 2b) time: Time patient last seen well to the time of successful vessel recanalization (based on angiogram).

  15. Exploratory: Median time measurements (Emergency Medical Services call-to-door time)

    Time frame: Peri-procedural time

    Emergency Medical Services call-to-door time: Time from the call to Emergency Medical Services to the time the patient arrives at the Comprehensive Stroke Center door (total ambulance service time)

  16. Exploratory: Median time measurements (Comprehensive Stroke Center notification call-to-door time)

    Time frame: Peri-procedural time

    Comprehensive Stroke Center notification call-to-door time: Time from notification call to the Comprehensive Stroke Center stroke team to the time the patient arrives at the Comprehensive Stroke Center door

  17. Exploratory: Median time measurements (imaging-to-thrombolytics administration time)

    Time frame: Peri-procedural time

    Imaging-to-thrombolytics administration time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to the time of start of thrombolytics administration.

  18. Exploratory: Median time measurements (imaging-to-arterial puncture time)

    Time frame: Peri-procedural time

    Imaging-to-arterial puncture time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to the time the skin of the patient is touched to perform first arterial puncture

  19. Exploratory: Median time measurements (Door-to-device deployment (first pass) time)

    Time frame: Peri-procedural time

    Door-to-device deployment (first pass) time: Time patient arrives at the CSC door to the time of device deployment (first pass).

  20. Exploratory: Median time measurements (imaging-to-successful reperfusion (eTICI ≥ 2b) time)

    Time frame: Peri-procedural time

    Imaging-to-successful reperfusion (eTICI ≥ 2b) time: Time from initial triage imaging acquisition (i.e. non-contrast CBCT or CT/MR) to time of successful vessel recanalization (based on angiogram).

  21. Exploratory: Median time measurements (arterial puncture-to-successful reperfusion (eTICI ≥ 2b) time)

    Time frame: Peri-procedural time

    Arterial puncture-to-successful reperfusion (eTICI ≥ 2b) time: Time the skin of the patient is touched to perform first arterial puncture to the time of successful vessel recanalization.

  22. Exploratory: Median time measurements (arterial puncture-to-end-of-EVT procedure (catheter out) time)

    Time frame: Peri-procedural time

    Arterial puncture-to-end-of-EVT procedure (catheter out) time: Time the skin of the patient is touched to perform first arterial puncture to the time of the catheter is taken out (total EVT procedure time)

  23. Exploratory: Degree of disability (other clinical outcome)

    Time frame: At discharge or 5-7 days post-procedure, and at 90 ± 14 days post-procedure

    Defined as modified Rankin Scale score (scores 0-6) distribution at discharge or at 5-7 days post-procedure, whichever comes first, and at 90 ± 14 days.

  24. Exploratory: NIHSS (other clinical outcome)

    Time frame: At admission (baseline), 24(-12/+24) hours after randomization, discharge or at 5-7 days post-procedure, whichever comes; and at 90 ± 14 days post-procedure

    The National Institutes of Health Stroke Scale is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0

  25. Exploratory: Functional independence (other clinical outcome)

    Time frame: At 90 ± 14 days post-procedure

    Functional independence defined as mRS ≤ 2 at 90 days. The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).

  26. Exploratory: UW-mRS (other clinical outcome)

    Time frame: At 90 ± 14 days post-procedure

    Utility-Weighted modified Ranking Scale. The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).

  27. Exploratory: Dichotomized mRS score (other clinical outcome)

    Time frame: At 90 ± 14 days post-procedure

    Dichotomized mRS score (0-3 versus 4-6). The scale runs from 0-6, running from perfect health without symptoms (0) to death (6).

  28. Exploratory: Infarct volume (other clinical outcome)

    Time frame: At 24 (-12/+24) hours post-procedure

    Infarct volume evaluated on CT or MRI

  29. Exploratory: Dramatic early favorable response (other clinical outcome)

    Time frame: At 24 (-12/+24) hours after randomization

    Defined as an NIHSS score of 0-2 or NIHSS improvement ≥ 8 points. The National Institutes of Health Stroke Scale is a tool used to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0

  30. Exploratory: Successful vessel recanalization (other clinical outcome)

    Time frame: At the end of the endovascular procedure

    Defined as expanded Thrombolysis in Cerebral Infarction) (eTICI) grade 2b, 2c or 3 on the post-procedure angiogram

  31. Exploratory: X-ray radiation exposure (other clinical outcome)

    Time frame: On day 1

    Total X-ray Radiation Exposure measured as effective dose (mSv).

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Philips Clinical & Medical Affairs Global

Industry

Registry information

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Jan 8, 2021
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.